One-Stop Shopping (setravis)

[setravis]

TOP STORIES.......


UTStarcom Announces
Contract with India's Bharti Airtel
UTStarcom, Inc. (UTSI) announced a contract to supply its industryleading
RollingStream(TM) end-to-end IPTV solution to Bharti Airtel,
one of India's leading integrated telecommunications service providers
with more than 46 million customers. UTStarcom's RollingStream solution
will enable Bharti Airtel to offer a completely new service to its
customers consisting of live broadcast television, time-shifted TV and
video-on-demand (VoD) bundled with the operator's existing broadband
and voice services, which can all be consolidated into a single bill sent
to customers at the end of each month. Airtel expects to offer this new
service bundle to customers in Gurgaon and the National Capital Region
(NCR) by the end of the year. The service will also be rolled out in
a phased manner across eight additional regions in the country.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>


Composite Technology Subsidiary
Ships First 2 Megawatt Wind Turbine
Composite Technology Corporation (CPTC) announced that its subsidiary
DeWind Inc., has shipped the first 2 megawatt D8.2 wind turbine for
commercial applications from its operations in Germany. This turbine
order has begun its long journey to San Juan, Argentina, where it will be
installed at 4,000 meters elevation near the customer's Veladero mining
operations and will be the only multi-megawatt turbine operating at that
elevation.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>


Depomed To Cut One-Fourth of its
Staff Due To Phase III Study Results
Depomed, Inc. (DEPO), will be reducing 25% of its staff. CEO Carl Pelzel,
said, "This reduction was difficult because it affects so many of our
loyal, talented and hardworking employees. However, it was necessary
in order to conserve cash and align our workforce to our needs in light
of the disappointing results of our Phase 3 study in postherpetic neuralgia.
The reduction in force is in addition to other ongoing cost-cutting
initiatives."
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>


Enterra Energy Announces the
Suspension of Monthly Distribution Payments
The Board of Directors of Enterra Energy Corp., the administrator of
Enterra Energy Trust (ENT) today announced that it has suspended its
monthly distribution payment to unitholders until further notice, but for
a minimum period of six months, commencing with the distribution to
unitholders on October 15, 2007. The Trust currently is in compliance
with all financial covenants under its credit facilities.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>


Vasogen Reports Plans for Confirmatory
Study Supporting Heart Failure Treatment
Vasogen Inc. (VSGN) announced plans for a confirmatory study that
would support an application for regulatory approval in the United States
of its Celacade technology for the treatment of patients with NYHA Class
II heart failure. The planned trial design indicates that as few as 300 patients
could provide sufficient data to confirm the finding of the phase III
ACCLAIM trial which demonstrated a 39% reduction (p equals 0.0003)
in the risk of death or cardiovascular hospitalizations for the large prespecified
subgroup of 689 NYHA class II heart failure patients.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>


Medical Discoveries Acquires
Privately-held Global Clean Energy Holdings
Medical Discoveries (MLSC) announced it has acquired privately-held
Los Angeles-based Global Clean Energy Holdings LLC, a subsidiary
of Mobius Risk Group LLC. The purchase includes certain proprietary
rights, intellectual property and other rights relating to both the cultivation
and production of feedstock oil from the Jatropha plant, and the
commercialization of the oil for the production of biodiesel. Medical
Discoveries has terminated its prior drug development operations, appointed
new members of management and directors, and intends to
change its name and ticker symbol to reflect its new focus on the biodiesel
alternative energy market. The Company also intends to relist on
the Over-the-Counter Bulletin Board.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

[setravis]

▲TOP NEWS GAINERS.......

SYMBOL    CLOSE    %GAIN    VOLUME    NEWS
MLSC $0.070 159.26% 1,171,700 Acquires Privately-held Global Clean Energy Hldgs
UTLS $0.350 150.00% 66,000 Element Service to Complete Reverse Merger w/ Utilisource by Jan. 1
INSP $17.380 31.17% 7,307,000 Sale to Idearc Nets $225M and Shareholder Payout
UTSI $3.090 14.87% 5,406,300 Announce Contract with Bharti Airtel
GNTA $1.390 8.59% 1,931,600 Initiates Clinical Trial w/ Oral Drug to Treat Bone Disease
CPTC $1.850 6.94% 3,375,100 Subsidiary Ships First 2 Megawatt Wind Turbine
RFIL $6.530 5.51% 44,300 Q3 EPS 12c vs 11c EPS +9% Y/Y
WPCS $10.740 4.78% 66,900 Q1 EPS 16c vs 16c Meets 16c Est
ULBI $11.630 4.59% 140,000 Awarded $24M Contract from Raytheon
VSGN $2.330 4.49% 135,000 Plans for Confirmatory Study Supporting Heart Failure Treatment
EGY $4.390 4.28% 646,800 Board Authorizes Buyback of Up to $20M
CTDC $6.150 2.50% 2,750,600 Announce Proposed Acquisition of Shenzhen Soyin Electrical Appliance
EJ $19.970 2.46% 1,479,300 CIBC Starts @ Sector Outperform

[setravis]

I had posted this in the Premium Service, Main Portfolio, located in the thread..."About the general market slump yesterday" created by David Randolph.
I got to thinking, I should share this with all here @ 3SOF.
So I placed a copy of that post here.......
<><><><><><><><><><><><><><><><><><><><><><>

How the herd got fleeced on Wall Street,
Investors hit by big "volatility stick" 

First let me say that I've never yet seen a significant stock market pullback or correction (like the one we've just seen) that didn't end with an overblown financial scare story.
Near the bottom of the last major pullback in late February/early March the media was pounding the drums of a housing collapse and a sub-prime mortgage meltdown. We were told by the press that this crisis would soon spill over into all major sectors of the economy and that financial markets would melt, including a crash in the stock market.

Did the stock market crash? Did the economy falter and the unemployment rate skyrocket? Did the housing market collapse even worse than it already had? The answer to each of these questions of course is "No!" What happened instead is that the stock market as measured by the S&P 500 found a strong level of support and took off from there to make an all-time high, traveling almost 200 points in the process.

This is how the media operate (on fear) and they make their money by telling people what they want to hear, which is always in line with the latest crisis of the hour.

There are a couple of things I've learned about the mainstream financial press over the years as it relates to the stock market. One is that you can always count on the press to spread fear and panic after a major market decline. There is currently no shortage of negatives the media can direct our attention to in order to get us worried: the oil price, the "credit crunch," the sub-prime meltdown and housing recession, the weak dollar, etc.

Too many investors have been under the media's spell as these investors have been too scared to take advantage of the two great buying opportunities the market has presented them with this year. The first one was in March and the other in August. This really isn't at all surprising given that most mainstream investors are under the control of the media, psychologically speaking (see Lonny Kocina's book, Media Hypnosis, for a more in-depth discussion of this concept of media mind control). As Don Hays puts it, "The news is the camouflage that drives the herd crazy."

Volatility is also used as a weapon against mainstream investors. It can be used, for instance, to clear small investors out of the way so that big money traders can scoop up shares at bargain prices. Most small investors simply can't afford a prolonged exposure to market volatility and are often forced to sell out to the big money traders, who in turn are more than happy to relieve the small traders of their shares at cheap prices.

From a psychological standpoint, volatility has been shown to increase anxiety and paranoia in most investors. It makes them more likely to let go of a potentially profitable long position at the slightest hint of weakness. Ironically, this helps bolster the stock market's support since an increase in worry has been shown to strengthen the market's "Wall of Worry." It comes as no surprise then that the recent market bottom was been accompanied by a huge increase in bearish sentiment, worry and volatility. It's as if investors have been collectively hit by a big "volatility stick" and are afraid to go anywhere near the stock market.

To underscore the point I've been trying to make that the most important role of market volatility, let's discuss the correlations between volatility increases and insider buying of stocks during market panics. Other than the obvious benefits that increased volatility confers to insider traders in making short term capital gains, it can also be used as a weapon to scare away the small investors from participating in a market uptrend as we've looked at here. Additional proof of this is the comparison that can be made between the Gambill Oscillator, which measures insider buying, and the Volatility Index.

The Gambill Oscillator tracks corporate insider activity in the Russell 3000 stocks. Along with the VXO, the Gambill Oscillator is showing the highest level of insider buying since the March 2003 bear market low. Since 2002 when this indicator was first created, whenever the oscillator went above 25% (which it did in the latest correction), the stock market was up over 10% in the coming six months and up 22% over the next year. The Gambill Oscillator hit a high reading of 75% during the broad market decline.

Another point worth making is that since 1990, whenever the Volatility Index has been between 30 and 40, as it was during the recent correction, the stock market has been up by an average of nearly 11% over the next six months. Moreover, the market's gains over the following 12 months has been an average 16.2%. This compares with average "normal" market returns of 4.8% and 10.2%, respectively, over the 6-month and 12-month time frames.

Bolstering this bullish stock market outlook based on the insider sales data is a recent report by a respected financial newspaper. According to the Financial Times, total insider buying in the U.S. stock market reached $252 million in August, the highest level since 2003. This compares to a seasonal average of $186 million. At the same time, insider sales have dropped sharply from a four-year monthly average of $4 billion to $2.9 billion.

Volatility can indeed be used as a "big stick" to hit small investors with and send them running for cover. But this stick has two edges and the end result of the recent volatility spike will be positive for stocks.

[setravis]

TOP STORIES.......

(KMAG)
KMA Global Solutions Gaining Traction
with Electronic Article Surveillance Labels
Thursday's action was dominated with talk on Capitol Hill in testimony
delivered to the House Financial Services Committee by Fed Chairman
Bernanke and Treasury Secretary Paulson. Rhetoric revolved around
reform regarding government sponsored enterprises, Fannie Mae and
Freddie Mac. Much of the talk regarded a lifting of the portfolio cap and
also a lifting on the size of the loans that these GSE's could buy. In
the small cap space, one company has had a fairly busy month. KMA
Global Solutions International Inc. (KMAG) is a leading worldwide manufacturer
and supplier of Electronic Article Surveillance (EAS) labels
for the multimedia, retail apparel, health/beauty aids, soft goods, and
over-the-counter pharmaceutical industries. KMAG provides low cost
solutions for retail protection against inventory theft, offering customized
labels that use a variety of patented formats to meet unique packaging
needs. In late August, the Company announced a significant expansion
to an agreement initiated last year, through which the company
supplies custom sewn-in Electronic Article Surveillance (EAS) source
tagging solutions to the vendors of a leading International casual wear
apparel manufacturer and retailer. The program was piloted for stores in
Canada, however having experienced a significant amount of success
as a result of the program, this well-known brand has decided to expand
the program to other major markets in its enterprise. Originally slated to
protect some 10 million pieces of apparel, the expansion will see that
figure leap to around 50 million pieces per year. In early September, the
Company announced that it was continuing to add well known retailers
to their growing list of clients but couldn't divulge their names for
security reasons. A few days later, the Company announced the receipt
of $1,000,000 through the exercise of existing investor warrants. This
brings the total amount received by the company from its January 2007
financing to more than $2,000,000. The Company noted that it is utilizing
proceeds received from the exercise of the warrants to purchase additional
EAS manufacturing equipment, as well as equipment upgrades.
Additionally, KMAG is making improvements at its new Hong Kong facility
to increase production and distribution capacity. The Company then
reported their 10-Q for the quarter ended July 31st that displayed a year
over year sales decline, but shortly there after, they reported that booked
orders, sales revenues in August would be the highest month on record
in the Company's history. Noted as the cause was new customers coming
on stream in August and the seasonal demands of KMAG's U.S.
based retailers, sales in month of August were more than 200% higher
than sales in August 2006. The Company has announced this week of
a deal supplying one million of their DUALTag products to Sony's DADC
division, which produces digital products for its gaming systems and
an allowance of a patent application from the United States Patent and
Trademark Office (USPTO) regarding KMAG's non-provisional application
for a patent on its DUALTag(tm) product. The application has been
examined and is allowed for issuance as a U.S. patent. Pending payment
of associated fees to the USPTO, KMA anticipates that it will be
granted patent rights in the DUALTag. In any event, the Company has
been fairly active over the past months announcing a variety of news.
With any follow through to Thursday's 'paint the tape' gain of 14%, the
name could become one to follow. Investors would be wise to watch.
<><><><><><><><><><><><><><><><><><><><><><><><><><>

(KAL)
Callisto Completes Enrollment for Ph II
Trial of Atiprimod for Neuroendocrine Cancer
Callisto Pharmaceuticals, Inc. (KAL) hit a 52-week low in Thursday session
following the announcement of the completion of enrollment in its
Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine
carcinoma (advanced carcinoid cancer). The primary objective
of the Phase II clinical trial is to evaluate efficacy of Atiprimod in
patients with low to intermediate grade neuroendocrine carcinoma who
have metastatic or unresectable cancer and progression of their disease
despite standard therapy, Novartis' (NVS) Sandostatin(R) LAR(R)
(octreotide). Efficacy evaluations include the measure of target lesions
and the quantization of symptom relief. Approximately 7,000 cases of
carcinoid cancer are diagnosed in the U.S. annually. Carcinoid tumors,
or carcinoids, originate in hormone-producing cells of the gastrointestinal
(GI) tract, the respiratory tract, the hepatobiliary (liver) system and
the reproductive glands. The most common site of origin is the GI tract,
with tumors often developing in the rectum, and other sections of the
small intestine. Carcinoid tumors that metastasize to the liver have a
poor prognosis. Traditionally, chemotherapy relieves symptoms in less
than 30% of cases of metastatic carcinoid tumors, usually for less than
1 year. Carcinoid tumors typically produce a condition called "carcinoid
syndrome," which is caused by the release of hormones by the tumors
into the blood stream. The symptoms vary depending on which hormones
are released by the tumors, but typically include diarrhea, facial
flushing, wheezing, abdominal pain and valvular heart disease. Atiprimod,
exclusively licensed from Genzyme Inc. (DNA), is also in a Phase
I/IIa human clinical trial for relapsed or refractory multiple myeloma.
Another anti-cancer drug of Callisto, L-Annamycin, is being developed
as a treatment for forms of relapsed or refractory acute leukemia, a
currently incurable blood cancer. L- Annamycin has a novel therapeutic
profile, including potential activity against multi-drug resistant tumors
and significantly reduced cardiotoxicity, or damage to the heart, compared
to currently available drug alternatives. Callisto also has a proprietary
drug Guanilib in preclinical development for gastro-intestinal
disorders such as chronic constipation and irritable bowel syndrome.
As of June 30, 2007, the Company had an accumulated deficit of $64.4
million and cash of $689,000. Callisto recently closed a private placement
of 1,124,550 shares of Series B Convertible Preferred Stock and
22,491,000 warrants to certain investors for aggregate gross proceeds
of approximately $11.2 million. The Warrants are immediately exercisable
at $0.70 per share and are exercisable at any time within three
years from the date of issuance.

[setravis]

NEWS MOVERS.......

▲TOP NEWS GAINERS


SYMBOL    CLOSE    %GAIN    VOLUME    NEWS
HTLJ $0.250 38.89% 72,400 Subsidiary Awarded Two Contracts
PTLD $0.060 20.00% 760,600 Announces Acquisition of Angel Construction, Re-structures Liabilities
SHOR $16.500 17.19% 596,900 JP Morgan Starts @ Overweight; Analyst Notes
CHIP $4.000 14.61% 296,900 Generate Initial Revenue from Operations Ahead of Expectations
URZ $3.800 14.46% 415,500 To Acquire 81% Stake of Mineral Properties in Powder River Basin
APOG $27.440 11.64% 1,631,400 Q2 Adj EPS 40c vs 26c EPS +54% Y/Y; Guidance Varies from Consensus
NTO $6.600 10.74% 7,233,200 Offer to Acquire Yamana Gold Amended
VIAC $4.830 10.53% 193,200 Positive Data re Umbilical Cord blood for Sickle Cell and Thalassemia
PKE $32.950 7.19% 248,700 Q2 Adj EPS 45c vs 42c Beats 39c Est
NTCT $9.500 4.17% 400,300 Announces Revised Guidance for Second Quarter of Fiscal 2008
SDGL $0.101 3.06% 2,171,800 Receives $11.72 Million Contract
GLDC $3.090 2.83% 57,000 Q1 EPS 7c vs 2c EPS +250% Y/Y
AMN $102.690 2.78% 137,500 Q3 Adj EPS $2.27 vs $1.91 EPS +19% Y/Y

[setravis]

▼TOP NEWS LOSERS.......


SYMBOL    CLOSE    %LOSS    VOLUME    NEWS
BBAO $0.070 -61.11% 9,196,900 Files for Reorganization Under Chap 11 to Maintain Ongoing Operations
BCRX $8.000 -32.09% 6,563,900 Caris & Co Cuts to Average from Above Average; Analyst Notes
SYMD $0.830 -20.95% 1,218,500 Receives FDA Panel Recommendation for REPEL Adhesion Barrier
COT $8.210 -19.19% 2,054,500 Market Conditions Cause Lower Earnings Expectations for 2007
ETLY $0.430 -17.31% 985,100 Agreement to Acquire Innergy Power Corp.
SFN $8.120 -14.44% 795,900 Goldman Sachs Cuts to Sell from Neutral
ACIW $23.510 -11.22% 3,078,100 Q3 Adj EPS 10c vs 31c Misses 28c Est; Guidance Below Consensus
MNRO $34.490 -8.00% 175,800 Annouces Business Update for Second Quarter 2008
CVV $4.850 -7.62% 195,300 Prices Public Offering; Switching Listing to Nasdaq
DDMX $24.480 -5.19% 55,400 Q4 EPS 38c vs 31c Beats 36c Est; Guidance Varies from Consensus
KSP $39.500 -5.16% 237,300 Announces Public Offering of 3 Million Common Units
PIR $6.130 -4.67% 1,024,200 Q2 EPS (49c) vs (84c) Misses (44c) Est
CDI $28.500 -2.83% 206,100 Announces Sale of Todays Staffing Subsidiary

[setravis]

TOP STORIES.......


Progen Opens Lower on Disappointing
PI-88 Trial for Non-Small Cell Lung Cancer
Shares of Australian-based Progen Pharmaceuticals, Ltd. (PGLA)
opened the session lower after announcing that its Phase 2 trial of PI-88
in combination with the chemotherapeutic agent docetaxel to patients
with advanced non small cell lung cancer did not meet its primary endpoint
of significantly improving the progression-free rate at six months
compared to docetaxel alone. The trial also did not meet its secondary
endpoints of improvement in time to progression, response rate, overall
survival and quality of life measures. The overall data from this trial suggests
that no further investigation of PI-88 in combination with docetaxel
in patients with non small cell lung cancer that have failed platinum
based first line therapies is warranted. Progen's weakness on Monday
may have been tempered somewhat by the FDA's decision to award
Fast Track status for PI-88 for the prevention of tumor recurrence following
curative liver resection in patients with hepatocellular carcinoma.
The most common causes of this cancer are related to chronic infection
with hepatitis B and C. No products have been approved by the FDA to
prolong the time a patient remains disease free following surgery. PI-88
recently received positive opinion from European Committee for Orphan
Medical Products recommending the granting of orphan medicinal product
designation for PI-88 for the treatment of hepatocellular carcinoma.
"We remain committed to the ongoing development of PI-88, especially
given the exciting Phase 2 data seen in the primary liver cancer trial,"
said Justus Homburg, Progen's Chief Executive Officer. PI-88 has also
shown evidence of benefit in patients with melanoma, multiple myeloma
and prostate cancers. Phase 2 PI-88 results from prostate and melanoma
trials are expected in the first half and second half of calendar
2008, respectively. PI-88 may be more active for tumors that are at an
earlier disease stage. It controls tumor growth by limiting new blood vessel
formulation. It also limits cancer spreading. The anti-angiogenesis
class compounds (e.g. Genentech's (DNA) Avastin(R) and Bayer (BAY)
and Onyx's (ONXX) Nexavar(R), and Pfizer's (PFE) Sutent(R)) are estimated
to generate up to $10B in sales by 2010. The Company's PI-166
has been in-licensed for clinical development for the treatment of endstage
and inopearable primary liver cancer and is currently undergoing
Phase Ib clinical development in Australia.
<><><><><><><><><><><><><><><><><><><><><><><><><><>


NexMed Files NDA w/FDA for
Topical Alprox-TD(R) in Erectile Dysfunction
NexMed, Inc. (NEXM) filed a New Drug Application (NDA) for its topically
applied Alprox-TD(R) (alprostadil) cream for the treatment of
erectile dysfunction with the FDA. Erectile dysfunction is a highly
prevalent medical disorder that is estimated to affect over 152 million
men worldwide. The Company is focused on patented topical pharmaceutical
products based on a transdermal enhancement drug delivery
technology known as NexACT(R), which may enable an active drug to
be better absorbed through the skin. NexACT(R) overcomes the skin's
natural barrier properties and enabling high concentrations of the active
drug to rapidly penetrate the desired site. The NexACT technology also
has wide-ranging applicability in the development of transdermal dosage
forms such as patches, creams, gels, ointments, lotions, solutions
and intranasal sprays. The Company expects to receive a $3M milestone
payment from Novartis in early 2008. NexMed is also developing
Femprox(R), which is an alprostadil-based cream product intended
for the treatment of female sexual arousal disorder. The Company has
completed one U.S. Phase 2 study and a 400-patient study in China.
The Company does not intend to conduct additional studies for this
product until it has secured a co-development partner. Alprox-TD has
been selling in China and in Hong Kong since October 2001 and April
2002, respectively, under the Befar(R) name. NexMed receives modest
royalty payments for sales. Sales of Befar have been limited because
China has a limited number of patients who can afford erectile dysfunction
treatments. More than $150 billion in brand-name drug products
will be coming off patent by 2015. This could create opportunities for the
conversion of these products from injectable or oral dosage forms into
topical forms of creams or patches. The NexACT technology could also
enhance established brands, with the goal of extending product patent
life while enhancing efficacy and patient compliance.
<><><><><><><><><><><><><><><><><><><><><><><><><><><>


Baird Says Investors Seem Confused
re Array BioPharma Agreement w/Celgene
Shares of Array BioPharma Inc. (ARRY) declined in Monday's session
despite announcing a worldwide strategic collaboration with Celgene
Corporation (CELG) for the discovery, development and commercialization
of novel therapeutics in cancer and inflammation. Array said that Celgene
will make an upfront payment of $40 million to Array, and, in return,
Array will grant Celgene an option to select drugs developed under the
collaboration that are directed to two of four mutually selected discovery
targets. Additionally, Array is entitled to receive, for each drug, potential
milestone payments of approximately $200 million, if certain discovery,
development and regulatory milestones are achieved and $300 million if
certain commercial milestones are achieved, as well as royalties on net
sales. According to Baird, "Investors seemed confused as to the scope
and nature of the agreement because the $40 million up-front deal does
not cover any of ARRY's current named or clinical programs. We see
this deal as a huge validation of ARRY's discovery platform, and would
be incremental buyers on this detail." The firm continues to see the
stock as "one of the industry's most appealing small-cap stories." Array
believes that there is significant synergy between cancer and inflammatory
disease research areas, and developing drugs in one of the areas
may lead to therapies in the other area. Inflammatory diseases include
a broad range of conditions, most of which are classified by the tissue or
organ where the inflammation occurs. These conditions include rheumatoid
arthritis, psoriasis, chronic obstructive pulmonary disease, fibrotic
disease, Crohn's disease, and congestive heart failure and arteriosclerosis,
among others. The Company has 10 programs in its development
pipeline, eight of which are wholly owned by the Company. The Company
has also out-licensed two cancer programs to Genentech, Inc. (DNA)
and three to AstraZeneca (AZN). Through collaborations, Array has also
invented drug candidates that are currently in clinical development including
InterMune, Inc.'s (ITMN) hepatitis C virus protease inhibitor and
Eli Lilly's (LLY) CHK-1 inhibitor. The Company's primary competitors in
the research and discovery, licensing, development and commercialization
of drug candidates, includes Arena Pharmaceuticals Inc. (ARNA);
Arqule (ARQL); Cytokinetics Inc. (CYTK); Exelixis Inc. (EXEL); Incyte
Corporation (INCY); Theravance, Inc. (THRX); and Vertex Pharmaceuticals
Inc. (VRTX). Injectable protein therapeutics currently on the market
for inflammatory disease include Amgen's (AMGN) and Wyeth's (WYE)
Enbrel(R); Amgen's Kineret(R); Centocor's Remicade(R); and Abbott's
(ABT) Humira(R). The worldwide market for targeted cancer drugs is
expected to grow to $47 billion by 2012, representing the cancer drug
market's fastest growing segment. New markets for replacement drugs
to treat painful inflammatory disorders, are likely to develop.

[setravis]

▲TOP NEWS GAINERS

SYMBOL    CLOSE    %GAIN    VOLUME    NEWS
DCNAQ $0.285 32.56% 1,167,100 Completes Sale of North American Coupled Products Business
ASTT $0.620 19.25% 154,700 Subsidiary Receives New Financing from Chinese Bank Worth $20M
EMED $0.670 17.54% 476,800 OTC Listing to be Approved, Seeks Litigation For Infringement of Product
SCEY $1.470 15.75% 2,521,000 Adds 8,695 Acres of Oil and Gas Properties in Kansas
CSIQ $8.690 14.64% 1,013,100 Signs Agreement with the Govt of Suzhou New District to Build Park
SPKL $0.770 11.59% 2,449,600 IPO Commences with 4,352,780 Shares; to Open 13 More Units in U.S.
ABAT $4.730 10.51% 665,600 Enters Contract with Wuxi Angell Autocycle Co. Worth $4.6M for Batteries
SVNT $14.950 6.10% 690,700 Files Universal Shelf Registration Statement w/ the SEC for $200M
KNSY $26.130 5.24% 160,500 Expands Stock Buyback Program; Allowed to Repurchase up to 25M Shrs
POWI $31.200 4.31% 318,800 Wins Patent Infringement Lawsuit Against Fairchild Semiconductor
FRG $10.600 3.41% 424,600 Acquires Shares of Newwest Gold
CTIC $3.830 2.41% 152,500 Begins Ph III Trial of XYOTAX (TM)
TMM $3.240 2.21% 651,600 Reaches Settlement with Kansas City Southern

[setravis]

Outstanding performers ripe for inclusion in your portfolio or watch list.
Currently undergoing technical or fundamental events likely to affect stock price.


Symbol        Last                           Event
EMC            20.51              Record Price Break Out
NEM            48.25              Record Price Break Out
AAPL         148.27              Record Price Break Out
CYTC           45.16              Record Price Break Out
PWI            26.25                    Trending Up
STX             25.91                    Trending Up
FRPT           18.45                    Trending Up
SOLF          12.21                    Trending Up
NICE          35.75                      OverSold
EMC           20.51                 Analyst Upgrade
MOT           18.04                 Analyst Upgrade
ARBA          10.85                 Analyst Upgrade

[setravis]

Currently undergoing technical or fundamental events likely to affect stock price.
Underperformers ready for a tumble,
If you like to play the short side........


Symbol          Last                      Event
AMR              20.77              Record Price Low
LEN              24.18               Record Price Low
ACXM           20.54               Record Price Low
PLCE            24.79               Record Price Low
AMR              20.77                Percent Loser
CFC              18.38                Percent Loser
ARRS            11.98                Percent Loser
ETW             18.01               Trending Down
MSZ              23.27               Trending Down
BARE            23.76               Trending Down
SWHC          18.13               Trending Down
CBG              28.58                OverBought
S                  18.29                OverBought
CLNE            15.52                OverBought
UNTD           14.14                 OverBought
AUY              12.17           Analyst Downgrade
RHT             19.00            Analyst Downgrade
CREE           30.76            Analyst Downgrade
FDRY           17.90            Analyst Downgrade

[setravis]

ENEI.OB
Receives Second Contract
in the Past Two Weeks
Wednesday's session saw the Dow in the green as news that
the auto giant GM and the UAW agreed to preliminary terms
effectively ending the strike for the time being. Many in the industry
believed the agreement between the two could cause
other automakers to cut health care costs as the pact with GM included plans
for an independent retiree health care trust. Following the news, shares gained
some 7%, which was also fueled by energy inventory reports showing large increases compared
to expectations.
In the small cap space, one company announced another contract in the vehicle arena though it
is in the alternative energy space.
Ener1, Inc. (ENEI) is an alternative energy technology company that is developing lithium ion
batteries for hybrid electric vehicles (HEV) at its 80.5% owned EnerDel subsidiary, commercial
fuel cell products through its EnerFuel subsidiary, and nanotechnology- based materials and
manufacturing processes for batteries and other applications at its NanoEner subsidiary.
The U.S. Department of Energy (DOE) announced on Wednesday that it had awarded Ener1's
EnerDel subsidiary a $2.5 million contract over two years for plug-in hybrid vehicle (PHEV) research.
The award is for the development of cells for 10 and 40 mile range PHEVs using nanophase
lithium titanate coupled with a high voltage Nickel-Manganese cathode material.
The deal was the second one announced in the past few weeks. On September 18th, the Company
announced that its EnerDel subsidiary was awarded a lithium-ion battery technology development
contract from the United States Advanced Battery Consortium (USABC), an organization
whose members are Chrysler LLC, Ford Motor Company and General Motors Corporation.
USABC awarded the contract in collaboration with the U.S. Department of Energy (DOE) to
develop lithium-ion battery technology for hybrid-electric vehicle applications. The 18-month contract,
valued at $6.5 million, is the second of a three-phase USABC program and requires a 50
percent cost share. EnerDel successfully completed Phase I in June.
"We are pleased to award this contract to EnerDel as part of USABC's battery technology research
and development program," said Don Walkowicz, executive director of USCAR in the
press release. "The program is essential to advancing the goals of the FreedomCAR and Fuel
Partnership, yielding both near and long-term benefits for hybrid-electric and hydrogen-fueled
transportation."
Subhash Dhar, President of Ener1, said in the release, "We are pleased that USABC has awarded
the Phase II contract based upon the success we have demonstrated in Phase I. The contract
award recognizes our efforts to date, and the funds will greatly help EnerDel to deliver potentially
breakthrough technology in finished product form." Ulrik Grape, Chief Executive Officer of EnerDel,
added, "We expect to deliver results that will meet and exceed the battery performance
requirements of USABC and the DOE and that will set a very high standard of performance in
the United States."
USABC is a consortium of the United States Council for Automotive Research (USCAR). Its mission
is to develop electrochemical energy storage technologies that support commercialization
of fuel cell, hybrid and electric vehicles. USABC has a cooperative agreement with the DOE for
research and development of battery technologies.
With the two contracts, the Company has effectively increased their revenue dramatically and
withstanding a positive result from their research and developing, become one investors would
be wise to watch.

[setravis]

TOP STORIES.......

(EBS)
Emergent BioSolutions Signs
Three Year HHS Contract Worth $448M
Emergent BioSolutions Inc. (EBS), announced that it has signed a three
year contract with the U.S. Department of Health and Human Services
(HHS), with a total value of up to $448 million. Components of the contract
include: $400 million firm fixed-price for delivery of 18.75 million
doses of BioThrax(R) (Anthrax Vaccine Adsorbed) for inclusion in the
strategic national stockpile (SNS); $34 million for receipt of regulatory
approval of 4-year expiry dating for BioThrax payable through a combination
of a lump-sum payment reflecting a price per dose increase
for certain doses delivered prior to approval and an increase in the per
dose price to be paid for doses delivered following approval; up to $11.5
million in milestone payments in connection with advancement towards
a post-exposure prophylaxis (PEP) indication for BioThrax; and, $2.2
million for logistics services and other related support.
____________________________________________________________


(GNLB)
Genelabs Technologies Announces
Commitments to Raise $23.7M in Capital
Genelabs Technologies, Inc. (GNLB) announced that it has obtained
commitments from several institutional investors to purchase approximately
12.9 million shares of its common stock and warrants to purchase
approximately 2.6 million shares of its common stock for gross
proceeds of approximately $23.7 million. The investors have agreed to
purchase the shares and warrants for $1.84 per unit (each unit consisting
of one share and a warrant to purchase 0.20 shares of common
stock). The exercise price of the warrants will be $2.08 per share. The
warrants will be exercisable at any time prior to the fifth anniversary of
the closing of the transaction. The closing of the offering is expected to
take place on October 1, 2007, subject to satisfaction of customary closing
conditions. Genelabs plans to use the proceeds from this financing
to support its ongoing hepatitis C virus (HCV) drug discovery programs
and for general corporate purposes. The proceeds will not be used to
fund a new phase III clinical trial of Prestara. Deutsche Bank Securities
Inc. acted as exclusive placement agent in the transaction.
____________________________________________________________


(NPSP)
NPS Pharmaceuticals Announces
License Agreement with Nycomed for GATTEX
NPS Pharmaceuticals, Inc. (NPSP) and Nycomed announced that they
have entered into a definitive agreement which licenses to Nycomed the
rights to develop and commercialize GATTEX(TM) (teduglutide) outside
the United States, Canada and Mexico for the treatment of gastrointestinal
disorders. NPS will retain the right to develop and commercialize
GATTEX in North America. Under the terms of the agreement, NPS
has the potential to earn up to $185 million plus royalties. As an upfront
payment, NPS will receive from Nycomed $35 million: a $10 million nonrefundable
commitment fee upon signing the agreement and $25 million
within two weeks following the announcement of topline results from
the recently completed Phase 3 study of GATTEX in patients with short
bowel syndrome (SBS), which is expected early in the fourth quarter of
2007. Nycomed has the right to end the collaboration within two weeks
of the announcement of these results and forego the $25 million payment.
______________________________________________________________


(KERX)
Keryx Enters Into Licensing Agreement
With Japan Tobacco and Torii Pharmaceutical
Keryx Biopharmaceuticals (KERX) announced that it entered into a licensing
agreement with Japan Tobacco Inc. and Torii Pharmaceutical
Co., Ltd.,JT's pharmaceutical business subsidiary, under which JT and
Torii will hold the exclusive rights for the development and commercialization
of its hyperphosphatemia drug in Japan. The drug is currently in
phase II clinical development in the United States under the name of
"Zerenex(TM). The licensing arrangement calls for JT and Torii to pay
to Keryx up to $100 million in up-front license fees and payments upon
the achievement of pre-specified milestones, including up to $20 million
in up- front payments and near-term milestones. In addition, upon commercialization,
JT and Torii will make royalty payments to Keryx on net
sales of the drug in Japan. JT and Torii will be responsible for the future
development and commercialization costs in Japan.

[setravis]

▲TOP NEWS GAINERS.......

SYMBOL    CLOSE    %GAIN    VOLUME    NEWS
CNIC $3.560 101.13% 8,165,900 SEC Closes Investigation; Recommends No Enforcement Action
NEP $1.000 33.33% 24,700 Raises $12.7 Million in New Financing
NPSP $6.000 18.81% 2,489,800 Announce Licensing Agreement with Nycomed for GATTEX
EBS $9.220 18.36% 1,465,100 Signs 3 Year HHS Contract Worth $448M
NAVI $8.940 16.25% 1,014,500 Q4 Adj EPS (4c) vs (11c) Meets (4c) Est; Guidance Above Consensus
WGAT $0.430 13.22% 299,300 Announces Additional Investment of $1 Million
XFML $8.780 11.42% 10,073,500 Yucaipa Signs Agreement to Buy Block of Shares; David Olson Joins BoD
DCU $1.950 11.42% 20,800 Q4 EPS 4c vs 2c EPS +100% Y/Y
TGA $4.999 8.67% 457,600 Closes Acquisition of 2 Privately Held Companies for $59M
LPHI $38.000 8.08% 341,800 Q2 EPS 46c vs 2c EPS +2,200% Y/Y
PLCE $25.800 7.54% 3,390,000 Buckingham Ups to Accumulate from Neutral; Sets Tgt @ $35
SMSC $38.740 7.25% 1,498,300 Q2 Adj EPS 50c vs 39c Beats 39c Est; Guidance In-Line with Consensus
GY $11.990 6.01% 870,100 Q3 Adj EPS 25c vs (26c) Beats 6c Est

[setravis]

▼TOP NEWS LOSERS.......

SYMBOL    CLOSE    %LOSS    VOLUME    NEWS
VG $0.960 -26.15% 12,396,300 Stanford Group Cuts to Sell from Hold; Cuts Tgt to $0.75 vs $2
VOXW $5.500 -21.54% 27,600 Q4 EPS 1c vs (63c) EPS +102% Y/Y
CGPI $9.350 -15.99% 2,681,900 Leerink Swann Cuts to Mkt Perform from Outperform
CMGI $1.390 -13.13% 29,409,900 Q4 EPS (1c) vs (1c) EPS 0% Y/Y; Guidance In-Line with Consensus
LTRX $0.990 -9.17% 188,900 President/CEO Nussbaum Resigns; CFO Sakai Named Interim
XTLB $1.670 -7.22% 40,100 Falls Under $10M Equity Minimum; To Contest Delisting from NASDAQ
TGB $5.100 -5.38% 2,304,400 Raymond James Cuts to Outperform from Strong Buy
ZRBA $6.850 -4.73% 29,800 Q4 Adj EPS 28c vs 30c EPS -7% Y/Y
URST $0.305 -4.69% 95,600 Enters Into Option and Joint Venture Agreement With Temex Corp
CCBEF $2.150 -3.15% 234,700 Closes $9.36 Million Financing
MTSN $8.770 -3.09% 776,000 Announces Updated Guidance for Third Quarter of 2007
IW $1.680 -2.33% 86,900 Closes $3M Private Placement Financing Agreement
CTIC $3.710 -1.07% 72,600 Announces Meeting Results; Expects FY07 Net Loss Consistent w/FY06

[setravis]

Market Awareness.......


• AeroGrow International Inc (AGWI)
Specializing in the research, development, manufacturing and marketing
of consumer products for the emerging 'Kitchen Garden' product category,
and the developer of the world's first Kitchen Garden Appliance, the Aero-
Garden™.



• Dental Patient Care America, Inc. (otcbb: DPAT)
Provides multiple services to independent dental practitioners and organizes
dentists through a combination of acquiring practice assets and providing
management services.



• Element 21 Golf Co (otcbb: EGLF)
Manufacture & markets advanced scandium golf equip characterized by
playability properties exceeding those of all other materials.



• Riverdale Oil & Gas Corp. (otc: RVDO)
Has positioned itself in the oil and gas industry as an acquirer of substantial
lease acreage in prolific oil and gas producing regions in the domestic
United States.
Real-